VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 1.4% – Here’s Why

Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) fell 1.4% during trading on Friday . The stock traded as low as $0.6301 and last traded at $0.6561. 50,971 shares were traded during trading, a decline of 64% from the average session volume of 142,873 shares. The stock had previously closed at $0.6651.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of VYNE Therapeutics in a report on Monday, May 4th. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Reduce”.

VYNE Therapeutics Trading Down 1.4%

The stock has a market cap of $21.88 million, a price-to-earnings ratio of -1.73 and a beta of 2.00. The company has a 50 day simple moving average of $0.64 and a 200-day simple moving average of $0.57.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.10. The company had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.20 million. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%. Equities analysts forecast that VYNE Therapeutics Inc. will post -1.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VYNE Therapeutics

A number of large investors have recently bought and sold shares of VYNE. Anson Funds Management LP bought a new position in shares of VYNE Therapeutics during the 4th quarter worth approximately $739,000. Nantahala Capital Management LLC acquired a new position in VYNE Therapeutics during the fourth quarter worth $580,000. T3 Companies LLC acquired a new position in VYNE Therapeutics during the fourth quarter worth $548,000. Baker BROS. Advisors LP bought a new position in VYNE Therapeutics in the third quarter valued at $285,000. Finally, ADAR1 Capital Management LLC grew its position in VYNE Therapeutics by 319.2% in the first quarter. ADAR1 Capital Management LLC now owns 1,063,899 shares of the company’s stock valued at $636,000 after purchasing an additional 810,108 shares in the last quarter. Institutional investors and hedge funds own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.